Detection and characterization of carbapenemase-producing Enterobacteriaceae in cancer patients: first Sri Lankan report of blaVIM in Enterobacteriaceae
The Journal of Infection in Developing Countries · 2024
DOI: 10.3855/jidc.19499 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infection in Developing Countries, 2024. Verfasst von Gayashan Chathuranga und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory Sciences, Faculty of Allied Health Sciences, University of Sri Jayewardenepura, Sri Lanka. Hauptthemen laut MEDLINE: beta-Lactamases, Enterobacteriaceae Infections, Neoplasms, Carbapenem-Resistant Enterobacteriaceae. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Sri Jayewardenepura.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Carbapenem-resistant Enterobacteriaceae (CRE) are an important cause of infections in cancer patients. The proportion of carbapenem resistance and the types of carbapenemase-encoding genes in Enterobacteriaceae isolated from cancer patients were determined in this study. Methodology: Bacteria isolated from adult, in-ward cancer patients with lower respiratory tract infections (LRTI), skin and soft tissue infections (SSTI), or urinary tract infections (UTI) were included in the study. Enterobacteriaceae were identified up to the species level by API® 20E test kits. Carbapenem resistance was defined as non-susceptibility to either imipenem or meropenem in the disc diffusion test. Major carbapenemase-encoding genes (blaKPC, blaNDM, blaOXA-48, blaIMP, and blaVIM) were detected by the GeneXpert® Carba-R real-time PCR instrument.
Results
Enterobacteriaceae comprised 57% (94/165) of the bacterial isolates. Carbapenem resistance among Enterobacteriaceae was 46.8% (44/94). Klebsiella pneumoniae (65.9%, 29/44) was the predominant CRE isolate followed by Escherichia coli (25%, 11/44). The majority of CRE isolates (72.7%, 32/44) had a meropenem MIC of ≥ 32 µg/mL. Carbapenemase-encoding genes were identified in 43 of the 44 CRE isolates. blaNDM was the most prevalent carbapenemase-encoding gene and was detected in 67.4% (29/43) of Enterobacteriaceae isolates. No isolate was positive for blaIMP. Sixteen (37.2%) isolates co-harbored more than one carbapenemase-encoding gene. Two Enterobacteriaceae isolates were found to harbor blaVIM.
Conclusions
Nearly all CRE isolated in this study were carbapenemase producers. This study documented the emergence of blaVIM harboring Enterobacteriaceae for the first time in Sri Lanka.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Laboratory Sciences, Faculty of Allied Health Sciences, University of Sri Jayewardenepura, Sri Lanka.
- Department of Microbiology, Faculty of Medical Sciences, University of Sri Jayewardenepura, Sri Lanka.
- Department of Pharmacology, Faculty of Medical Sciences, University of Sri Jayewardenepura, Sri Lanka.
Förderung
- University of Sri Jayewardenepura
Zitieren
APA
Chathuranga, G., Dissanayake, T., Fernando, N., & Wanigatunge, C. A. (2024). Detection and characterization of carbapenemase-producing Enterobacteriaceae in cancer patients: first Sri Lankan report of blaVIM in Enterobacteriaceae. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.19499
Vancouver
Chathuranga G, Dissanayake T, Fernando N, Wanigatunge CA. Detection and characterization of carbapenemase-producing Enterobacteriaceae in cancer patients: first Sri Lankan report of blaVIM in Enterobacteriaceae. The Journal of Infection in Developing Countries. 2024. doi:10.3855/jidc.19499
BibTeX
@article{Chathuranga2024,
author = {Chathuranga, Gayashan and Dissanayake, Thushari and Fernando, Neluka and Wanigatunge, Chandanie Amila},
title = {Detection and characterization of carbapenemase-producing Enterobacteriaceae in cancer patients: first Sri Lankan report of blaVIM in Enterobacteriaceae},
journal = {The Journal of Infection in Developing Countries},
year = {2024},
doi = {10.3855/jidc.19499}
}
EUVIMED